Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

PURPOSE: The poly(ADP-ribose) polymerase inhibitor rucaparib is approved for the treatment of patients with recurrent ovarian and metastatic castration-resistant prostate cancer; however, limited data are available on its use in patients with hepatic dysfunction. This study investigated whether hepa...

Descripción completa

Detalles Bibliográficos
Autores principales: Grechko, Nikolay, Skarbova, Viera, Tomaszewska-Kiecana, Monika, Ramlau, Rodryg, Centkowski, Piotr, Drew, Yvette, Dziadziuszko, Rafal, Zemanova, Milada, Beltman, Jeri, Nash, Eileen, Habeck, Jenn, Liao, Mingxiang, Xiao, Jim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236452/
https://www.ncbi.nlm.nih.gov/pubmed/33909097
http://dx.doi.org/10.1007/s00280-021-04278-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236452/
https://www.ncbi.nlm.nih.gov/pubmed/33909097
http://dx.doi.org/10.1007/s00280-021-04278-2

Ejemplares similares